Menu
Oncology Evolved
Engineering the Next Generation of Off-the-Shelf Cell Therapies
PIPELINE
PRE-CLINICAL
CLINICAL
CAR-T (Allogeneic)
T-ALL/LBL
WU-CART-007
Memory NK (Allogeneic)
AML
WU-NK-101
Solid Tumors
WU-NK-101 + mAb
Solid Tumors
WU-NK-201 Engineered
LATEST NEWS
Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress
-- WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events -- …
Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
— First Patient Dosed in this Global, Open-Label Study to Assess the Safety and Tolerability of WU-NK-101 in AML —…
Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress
-- First clinical data presented from WU-CART-007 program; data highlight promising safety profile and preliminary anti-tumor activity in patients with…
Copyright © 2023 Wugen. All Rights Reserved.
a COGNEO design